Navigation Links
REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body
Date:2/4/2008

e placebo-controlled period), AEs occurred at a higher incidence in the REMICADE groups (63 percent and 69 percent with 3 mg/kg and 5 mg/kg, respectively), compared with the placebo group (56 percent). The only clinically significant laboratory abnormalities that occurred more frequently in the REMICADE group compared with the placebo group were elevated liver enzyme tests. Serious AEs occurred at rates of 2 percent in the placebo group, 3 percent in the 5 mg/kg group and 1 percent in the 3 mg/kg group. AEs observed were generally consistent with those described in the prescribing information, including information regarding serious infections. Please see "Important Safety Information" below.

About SPIRIT

SPIRIT was a Phase 2, multi-center, double-blind, placebo-controlled study evaluating the use of REMICADE induction therapy in 249 people with severe plaque psoriasis who had previously received psoralen plus ultraviolet light A (PUVA) or systemic therapy for psoriasis. Trial participants were randomized to receive REMICADE 3 mg/kg, REMICADE 5 mg/kg or placebo at weeks 0, 2, and 6 and were assessed biweekly for 10 weeks. At week 26, patients whose Physician Global Assessment (PGA) score indicated moderate to severe disease (n=114) were eligible for one additional infusion of their assigned treatment to assess the safety of retreatment after a 20-week treatment-free period.

In the SPIRIT trial, the percentage of patients with one or more AE was higher in the REMICADE groups compared with placebo. Through week 30 of the SPIRIT trial, 63 percent, 78 percent and 79 percent of patients in the placebo, REMICADE 3 mg/kg and 5 mg/kg groups, respectively, reported one or more AE. The most commonly reported side effects versus placebo were upper respiratory tract infection (15 percent versus 14 percent), headache (15 percent versus 8 percent) and itching (12 percent versus 0 percent). A total of 6 percent of REMICADE-treated patients reported serious AEs
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents
2. TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
3. JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients
4. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
5. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
6. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
8. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
10. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
11. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 Imprimis Pharmaceuticals, ... company dedicated to delivering high quality and novel medicines ... that Chief Executive Officer Mark Baum will ... Craig-Hallum Alpha Select Conference in New York City.  Mr. ... Go Dropless™ campaign in ophthalmology. The presentation is ...
(Date:9/16/2014)... YORK , Sept. 16, 2014  Relmada Therapeutics, ... for the treatment of chronic pain, announced today that ... Kettering Cancer Center (MSKCC) in a series of animal ... a new tamper-resistant, extended release form of levorphanol.  Gavril ... for these studies. Dr. Pasternak said, ...
(Date:9/16/2014)... , N.J. and NEW PROVIDENCE, N.J. , ... experts will present a paper on the critical elements ... oxygen storage and deliver systems at the American Society ... be held at the Chicago Sheraton Hotel and Towers ... Derrick West , program manager of Hospital ...
Breaking Medicine Technology:Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3Linde Healthcare experts to present details on installation of medical oxygen storage and distribution systems at ASPE convention 2Linde Healthcare experts to present details on installation of medical oxygen storage and distribution systems at ASPE convention 3
... Cynosure, Inc. (Nasdaq: CYNO ), a leader ... non-invasive aesthetic applications, today announced that two of its ... have received key international regulatory clearances. ... the sale in Canada of the company,s SmoothShapes® XV ...
... 2011 Unilife Corporation ("Unilife" or the ... announced that it remains on schedule to commence initial ... and commence sales to pharmaceutical customers by the end ... Company successfully commissioned the cleanrooms at its state-of-the-art production ...
Cached Medicine Technology:Cynosure Receives International Marketing Clearances for New Cellulite, Laser Lipolysis Products 2Cynosure Receives International Marketing Clearances for New Cellulite, Laser Lipolysis Products 3Unilife on Schedule to Fill Initial Orders for Unifill Syringe 2Unilife on Schedule to Fill Initial Orders for Unifill Syringe 3
(Date:9/16/2014)... News) -- Including women older than 70 in national ... reduction in advanced forms of the disease, a new ... programs could result in older women being overdiagnosed and ... to screen older women for breast cancer should be ... of using mass screening, the decision to participate in ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Thousands ... against C.R. Bard, Inc. continue to move forward ... District Court, Southern District of West Virginia, Bernstein ... September 15, 2014, the Court has determined that ... the proceeding. The Order indicates that the first ...
(Date:9/16/2014)... Dennis Thompson HealthDay Reporter ... Food and Drug Administration is focusing on the "Low T" ... helping or harming the health of aging American males. ... FDA committees will discuss whether doctors are prescribing testosterone therapy ... hormone increases the risk of stroke and heart attack. ...
(Date:9/16/2014)... researcher Dr. Jeffrey Samet and Dr. Carlos Del ... five year, $5 million grant from the National ... Improving Physician Opioid Prescribing for Chronic Pain in ... most commonly abused substances in the U.S. (after ... now exceed deaths from motor vehicle crashes. Prescription ...
(Date:9/16/2014)... SAMHSA, the federal Substance Abuse and Mental Health Services Administration, ... substance abuse and mental health issues on the communities of ... National Recovery Month, also simply Recovery Month, with its main ... in recovery. It also seeks to educate Americans on ... help those with substance abuse issues live a healthy and ...
Breaking Medicine News(10 mins):Health News:Some Benefits of Screening Elderly Women for Breast Cancer Questioned 2Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 2Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 3Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 4Health News:FDA to Probe Testosterone Therapy Claims, Safety 2Health News:FDA to Probe Testosterone Therapy Claims, Safety 3Health News:FDA to Probe Testosterone Therapy Claims, Safety 4Health News:Narconon Arrowhead Booklet Offers Tips During Recovery Month 2Health News:Narconon Arrowhead Booklet Offers Tips During Recovery Month 3
... the dentist for what you think is a routine checkup ... root canal. Though it,s a term you,ve probably heard before, ... have several questions and feel apprehensive about your upcoming procedure. ... time. The Pennsylvania Dental Association (PDA) wants to help answer ...
... , WASHINGTON, Nov. 12 Over the next several weeks, ... a major step toward improving food safety for all Americans. ... organizations and groups representing victims of foodborne illness is sending ... Safe for the Holidays!" , Every year, millions of Americans ...
... Nov. 12 /PRNewswire-FirstCall/ -- Mesa Laboratories, Inc. (Nasdaq: ... has declared a regular quarterly dividend of $.11 per share ... The dividend will be payable December 15, 2009, to ... public in 1984 Mesa Labs has maintained strong cash positions ...
... , WASHINGTON, Nov. 12 Senate Majority Leader Harry Reid ... quality, affordable health care for all. , The Associated Press ... under review is asking individuals who earn more than $250,000 ... tax that goes to Medicare. This measure would bring in ...
... As hormone use declined, so did incidence of abnormal cells ... News) -- Declining use of hormone replacement therapy may be ... a known risk factor for breast cancer, new research suggests. ... found between atypical ductal hyperplasia -- abnormal cells in the ...
... new study published in the November issue of the ... breast cancer patients under 40 years old who undergo fertility ... of their disease when their care is coordinated in a ... surgeons, medical oncologists and reproductive endocrinologists is critical," said Lynn ...
Cached Medicine News:Health News:Painful Root Canals Are a Thing of the Past 2Health News:New Polls, Reports Highlight The Need To Update The U.S. Food Safety System And To 'Make Our Food Safe For The Holidays' 2Health News:New Polls, Reports Highlight The Need To Update The U.S. Food Safety System And To 'Make Our Food Safe For The Holidays' 3Health News:Reid Moves Toward Progressive Financing Measure to Help Fund Health Care Reform 2Health News:Less HRT, Fewer Cases of Possible Breast Cancer Precursor 2Health News:Less HRT, Fewer Cases of Possible Breast Cancer Precursor 3Health News:Fertility procedures need not delay breast cancer treatment for younger women 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: